High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens t...

FOLD reports preliminary fourth-quarter and full-year 2024 total revenues. The company also outlines key strategic goals for 2025.

Amicus Therapeutics, Inc.'s shares are down 15% recently despite a profitable 3Q24 and raised FY24 outlook, potentially due to market overreaction. The company markets Galafold for Fabry disease and P...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two comp...

Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settl...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two stocks is more attractive ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two companies is the...

FOLD's third-quarter 2024 earnings and sales beat the Zacks Consensus Estimate. The company raises its financial guidance for 2024.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall...

Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Marte...

Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.07 per share a year ago.

The consensus price target hints at a 51.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FOLD, CLPR and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 24, 2024.

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, B...

CLPR, HROW, FOLD, GTLB and TCOM have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2024.

The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lu...